Liquid blood test to predict first immunotherapy response
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether a “liquid biopsy” blood test can help predict how well first immunotherapy will work for people with stage IV lung cancer. It may help doctors choose the most effective treatment strategy sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed non-small cell lung cancer (NSCLC) from a biopsy
- You are age 18 or older
- Your lung cancer is advanced or has spread to stage IV
- You have not started any treatment yet for this advanced stage (treatment-naïve)
- Your tumor can be measured on a CT scan (there is something measurable to track)
- You have enough tumor biopsy tissue available for tumor testing, including PD-L1 and gene testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at a simple blood test to see if it can help track how well your immunotherapy is working. If you have advanced lung cancer and are getting a standard immunotherapy drug, you may be able to join.
This trial uses a special blood test to look for tiny cancer DNA to estimate your risk of the cancer getting worse after first immunotherapy. It aims to help doctors monitor progression earlier and more accurately in advanced lung cancer.
This trial tests whether a blood test (ctDNA) can help predict how well a combination of chemotherapy and immunotherapy (and sometimes radiation) works before surgery for non-small cell lung cancer. It aims to see if the blood test can detect small amounts of remaining cancer to guide further treatment.
This trial studies whether a simple blood test can predict how well your immune system will respond to immunotherapy (such as Keytruda or Opdivo). You may qualify if you have lung cancer (NSCLC) or advanced melanoma and are about to start this type of treatment for the first time.
This trial is looking at a blood test to predict how well combined immunotherapy and chemotherapy will work in people with advanced lung cancer. It uses a new marker called ETASTs to help guide treatment decisions.
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
Hear when a new Metastatic Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.